Table 3 Correlation between clinicopathological characteristics and DUSP1 methylation in breast tumour DNA and PBL DNAa.

From: DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk

Clinicopathologic characteristics

DUSP1 methylation (tumour tissue DNA)

DUSP1 methylation (PBL DNAa)

Methylated No. (%)

Unmethylated No. (%)

ORcrude (95% CI)b

P-value

Methylated No. (%)

Unmethylated No. (%)

ORcrude (95% CI)b

P-value

TNM Stages

   

0.886

   

0.327

 I

38 (60.3)

25 (39.7)

1.000

 

8 (8.0)

92 (92.0)

1.000

 

 II

113 (59.8)

76 (40.2)

0.978 (0.546–1.751)

0.941

11 (4.7)

221 (95.3)

0.572 (0.223–1.469)

0.246

 III & IV

42 (56.8)

32 (43.2)

0.863 (0.436–1.709)

0.674

3 (3.3)

87 (96.7)

0.397 (0.102–1.543)

0.182

Tumour invasion

   

0.566

   

0.110

 T0–T1

86 (61.0)

55 (39.0)

1.000

 

13 (7.3)

166 (92.7)

1.000

 

 T2–T4

107 (57.8)

78 (42.2)

1.140 (0.729–1.782)

 

9 (3.7)

234 (96.3)

0.491 (0.205–1.176)

 

Lymphnodes involved

   

0.506

    

 N0

103 (60.9)

66 (39.1)

1.000

 

11 (5.2)

201 (94.8)

1.000

 

 N1/N3

90 (57.3)

67 (42.7)

1.162 (0.747–1.808)

 

11 (5.3)

197 (94.7)

1.020 (0.432–2.408)

 

Metastasis status

   

0.950

   

0.999

 M0

186 (59.2)

128 (40.8)

1.000

 

22 (5.4)

389 (94.6)

  

 M1

7 (58.3)

5 (41.7)

1.038 (0.322–3.343)

 

0 (0.0)

11 (100.0)

  

Histological type

   

0.243

   

0.871

 Invasive

143 (57.4)

106 (42.6)

1.000

 

17 (5.3)

303 (94.7)

1.000

 

 Noninvasive

50 (64.9)

27 (35.1)

1.373 (0.807–2.335)

 

5 (4.9)

97 (95.1)

0.919 (0.330–2.556)

 

ER status

   

0.001

   

0.036

 Positive

113 (52.8)

101 (47.2)

1.000

 

12 (3.8)

301 (96.2)

1.000

 

 Negative

79 (71.8)

31 (28.1)

2.278 (1.389–3.7335)

 

10 (9.2)

99 (90.8)

2.534 (1.062–6.044)

 

PR status

   

0.003

   

0.013

 Positive

94 (51.9)

87 (48.1)

1.000

 

9 (3.2)

271 (96.8)

1.000

 

 Negative

98 (68.5)

45 (31.5)

2.016 (1.275–3.186)

 

13 (9.2)

129 (90.8)

3.034 (1.264–7.282)

 

HER2 expression

   

0.503

   

0.779

 Positive

127 (60.5)

83 (39.5)

1.000

 

15 (5.4)

261 (94.6)

1.000

 

 Negative

64 (56.6)

49 (43.4)

0.854 (0.537–1.357)

 

7 (4.8)

139 (95.2)

1.141 (0.455–2.865)

 

Molecular subtypec

   

0.001

   

0.108

 Luminal A

33 (44.0)

42 (56.0)

1.000

 

3 (2.7)

110 (97.3)

1.000

 

 Luminal B

81 (57.0)

61 (43.0)

1.690 (0.961–2.971)

0.068

9 (4.4)

197 (95.6)

1.675 (0.444–6.317)

0.446

 HER-2 enriched

46 (67.6)

22 (32.4)

2.661 (1.345–5.267)

0.005

6 (8.5)

65 (91.5)

3.385 (0.819–13.944)

0.092

 Basal-like

31 (81.6)

7 (18.4)

5.636 (2.205–14.406)

0.000

4 (12.5)

28 (87.5)

5.238 (1.108–24.763)

0.037

P53

   

0.649

   

0.151

 Positive

49 (61.2)

31 (38.8)

1.000

 

8 (8.1)

91 (91.9)

1.000

 

 Negative

143 (58.4)

102 (41.6)

0.887 (0.529–1.487)

 

14 (4.3)

308 (95.7)

0.517 (0.210–1.271)

 
  1. aPBL, peripheral blood leukocytes; bORcrude, odds ratio generated by univariate logistic regression; 95%CI, 95% confidence interval. cSubtypes were classified by immunohistochemical surrogates as basal-like (ER-, PR-, HER-2−, triple-negative), luminal A (ER and/or PR+, HER-2−), luminal B (ER and/or PR+, HER-2+), or HER-2 enriched (ER and PR−, HER-2+).
Back to article page